Pretax income is the income that a company earns before paying income taxes. Omeros's pretax income for the
three
months ended in Dec. 2024 was $-36.54 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-182.63 Mil.
Omeros's pretax margin was %.
During the past 13 years, Omeros's highest Pretax Margin was -82.50%. The lowest was -555.90%. And the median was -314.03%.
Omeros Pre-Tax Income Historical Data
The historical data trend for Omeros's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Omeros's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omeros's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Omeros's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Omeros's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-182.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omeros (NAS:OMER) Pre-Tax Income Explanation
Omeros's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
During the past 13 years, Omeros's highest Pretax Margin was -82.50%. The lowest was -555.90%. And the median was -314.03%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omeros Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Omeros's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OMER has been successfully added to your 